Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) has announced it will host a live webcast on Thursday, August 8, 2024, at 1:30 p.m. PT / 4:30 p.m. ET to report its second quarter 2024 financial results and provide a corporate update. The company, focused on addressing unmet needs in eye care through proven science and new technology, will make the webcast accessible to participants via a provided link. A recorded version of the call will be available on the website shortly after the webcast concludes and will remain archived for approximately 90 days.

News Market Reaction – TARS

-1.48%

-1.48% Session move

In the trading session that priced this news, TARS declined 1.48%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update.

Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the treatment of rosacea and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

When will Tarsus Pharmaceuticals (TARS) report its Q2 2024 financial results?

Tarsus Pharmaceuticals (TARS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, during a live webcast at 1:30 p.m. PT / 4:30 p.m. ET.

How can investors access Tarsus Pharmaceuticals' (TARS) Q2 2024 earnings webcast?

Investors can access Tarsus Pharmaceuticals' (TARS) Q2 2024 earnings webcast through a link provided by the company. The specific link is not mentioned in the press release but will likely be available on the company's investor relations website.

Will there be a replay available for Tarsus Pharmaceuticals' (TARS) Q2 2024 earnings call?

Yes, a recorded version of Tarsus Pharmaceuticals' (TARS) Q2 2024 earnings call will be available on the company's website shortly after the completion of the live webcast and will be archived for approximately 90 days.